Skip to articles
Semaglutide
Articles

Weekly medicine, distinct forms

An article collection on formulations, study results and the limits of comparison.

Semaglutide weight loss is more than a headline average

Weight, body composition and everyday strength describe different outcomes.

What the injection trial found

In STEP 1, adults with obesity, or overweight and a weight-related condition, without diabetes were assigned semaglutide injection or placebo. Placebo is a dummy treatment. Both groups received lifestyle support. At 68 weeks, average body-weight reductions were 14.9% with semaglutide and 2.4% with placebo.

Those are changes from each group’s starting weight. The time point and comparison matter as much as the larger percentage. A group average contains a spread of individual results; it does not describe the result of every participant. It also cannot establish the outcome of a different preparation carrying the semaglutide name.

The study concerned an injection. Oral evidence has its own studies and product information. The research article explains why comparing numbers across separate trials is different from comparing treatments within one trial. No percentage here serves as a target for a reader.

Appetite helps explain weight change

Semaglutide activates receiving points for the GLP-1 hormone signal, called receptors. The label describes reduced calorie intake through effects on appetite. This gives weight change a biological context, beyond the idea that it simply reflects determination or effort.

At the same time, reduced hunger and feeling too unwell to eat are different experiences. The digestive-effects analysis describes unwanted reactions in the injection studies. A lower scale reading cannot identify the cause of a change in eating, or show that the change is beneficial for an individual.

Weight, lean tissue and strength

A semaglutide body-composition report found changes in both fat and lean tissue. Lean tissue includes body components other than fat; it is not another name for a direct measurement of muscle strength. A total-weight result cannot separate all those components by itself.

A scan and an everyday task also answer different questions. Lifting luggage, walking up steps or carrying groceries involves function, not just a tissue category. The illustration on this page makes that distinction visible; it does not claim the trial measured those activities or that semaglutide improves them.

This is why a phrase such as pure fat loss would overstate the evidence. Equally, a measured decline in lean tissue does not establish a particular person’s strength loss. Each outcome needs the tool that actually measures it and the population in which it was measured.

An adult seen from behind lifts a small suitcase onto a train luggage rack.
An ordinary luggage lift illustrates physical function, which a body-composition scan does not measure directly.

Maintenance is a later question

In the STEP 1 extension, much of the lost weight returned on average after semaglutide and structured lifestyle support ended. The follow-up involved a smaller group than the original trial. It supplies information about what happened afterward while leaving many possible support arrangements untested.

STEP 4 used a different design: after a shared semaglutide treatment period, participants continued treatment or switched to placebo. The groups moved in different directions, with further average loss on continued treatment and regain after the switch. The starting point for that comparison was later than initial enrollment.

Neither study supplies a universal treatment length or proves a method for avoiding regain after stopping. The results belong to the interventions and follow-up actually studied. They also do not establish a tablet result simply because tablets contain the same ingredient.

Comparing another ingredient

SURMOUNT-5 directly compared tirzepatide and semaglutide in adults with obesity. The source notes identify the paper and its reported figures. That comparison concerns two active ingredients, not a conversion between semaglutide formulations and not a choice this article can make for a reader.

A compounded preparation lacks FDA approval and has a separate identity from a manufactured medicine studied in a trial. Weight outcomes for the latter do not validate the former. The formulation article explains why preparation identity comes before interpreting a prescription number. Weight remains an important outcome, with clear limits on what it can tell us alone.

Further Semaglutide articles